BR112017000714A2 - indols funcionalizados e substituídos como agentes anti-câncer - Google Patents

indols funcionalizados e substituídos como agentes anti-câncer

Info

Publication number
BR112017000714A2
BR112017000714A2 BR112017000714-2A BR112017000714A BR112017000714A2 BR 112017000714 A2 BR112017000714 A2 BR 112017000714A2 BR 112017000714 A BR112017000714 A BR 112017000714A BR 112017000714 A2 BR112017000714 A2 BR 112017000714A2
Authority
BR
Brazil
Prior art keywords
functionalized
cancer agents
indols
substituted
substituted indols
Prior art date
Application number
BR112017000714-2A
Other languages
English (en)
Inventor
Heaton Andrew
Eiffe Eleanor
Pottabathini Narender
Gunning Peter
Original Assignee
Novogen ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen ltd filed Critical Novogen ltd
Publication of BR112017000714A2 publication Critical patent/BR112017000714A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

a presente invenção se refere a compostos anti-tropomiosina, processos para o seu preparo, e métodos para o tratamento ou prevenção de uma doença ou desordem, tal como uma doença proliferativa (preferivelmente câncer), usando compostos da invenção.
BR112017000714-2A 2014-07-16 2015-07-16 indols funcionalizados e substituídos como agentes anti-câncer BR112017000714A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462025207P 2014-07-16 2014-07-16
US62/025,207 2014-07-16
PCT/AU2015/050400 WO2016008011A1 (en) 2014-07-16 2015-07-16 Functionalised and substituted indoles as anti-cancer agents

Publications (1)

Publication Number Publication Date
BR112017000714A2 true BR112017000714A2 (pt) 2018-01-09

Family

ID=55077744

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017000714-2A BR112017000714A2 (pt) 2014-07-16 2015-07-16 indols funcionalizados e substituídos como agentes anti-câncer

Country Status (16)

Country Link
US (1) US20170152226A1 (pt)
EP (1) EP3169683A4 (pt)
JP (1) JP2017520612A (pt)
KR (1) KR20170031097A (pt)
CN (1) CN106661005A (pt)
AU (3) AU2015227454B2 (pt)
BR (1) BR112017000714A2 (pt)
CA (1) CA2952557A1 (pt)
CL (1) CL2017000054A1 (pt)
CO (1) CO2017000065A2 (pt)
IL (1) IL250074A0 (pt)
MX (1) MX2017000613A (pt)
PH (1) PH12016502607A1 (pt)
RU (1) RU2017104856A (pt)
SG (1) SG11201610195UA (pt)
WO (1) WO2016008011A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074378A4 (en) * 2013-11-25 2017-05-10 Novogen Ltd. Functionalised and substituted indoles as anti-cancer agents
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
KR101862765B1 (ko) 2017-04-21 2018-05-30 한국화학연구원 N-아릴사이클릭아민 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
ES2950757T3 (es) 2017-10-06 2023-10-13 Forma Therapeutics Inc Inhibición de la peptidasa específica de la ubiquitina 30
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
JP2021520342A (ja) * 2018-04-03 2021-08-19 ベータ ファーマシューティカルズ カンパニー リミテッド 免疫調節物質、組成物及びそれらの方法
SG11202102815SA (en) 2018-10-05 2021-04-29 Forma Therapeutics Inc Fused pyrrolines which act as ubiquitin-specific protease 30 (usp30) inhibitors
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN110128415B (zh) * 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
CN110229091B (zh) * 2019-06-21 2022-11-22 天津科技大学 具有白三烯a4水解酶抑制作用的1，5-二取代吲哚衍生物及应用
CN113149897B (zh) * 2021-03-24 2023-10-31 福建省中科生物股份有限公司 一种2,6-取代-4-氧基萜酚吡啶类化合物及其制备方法和用途
WO2023049953A1 (en) * 2021-09-30 2023-04-06 TroBio Therapeutics Pty Ltd Substituted indole compounds and the use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1280580A (zh) * 1997-11-11 2001-01-17 辉瑞产品公司 用作抗癌药的噻吩并嘧啶和噻吩并吡啶衍生物
JP2003511378A (ja) * 1999-10-07 2003-03-25 アムジエン・インコーポレーテツド トリアジン系キナーゼ阻害薬
US6881737B2 (en) * 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0206215D0 (en) * 2002-03-15 2002-05-01 Novartis Ag Organic compounds
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2670717C (en) * 2007-01-08 2012-01-10 Suven Life Sciences Limited 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands
PT2488486T (pt) * 2009-10-13 2019-11-05 Ligand Pharm Inc Compostos de moléculas pequenas de mimética de fator de crescimento hematopoiético e utilizações dos mesmos
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
EP3074378A4 (en) * 2013-11-25 2017-05-10 Novogen Ltd. Functionalised and substituted indoles as anti-cancer agents

Also Published As

Publication number Publication date
JP2017520612A (ja) 2017-07-27
AU2015227454B2 (en) 2016-02-25
CN106661005A (zh) 2017-05-10
RU2017104856A (ru) 2018-08-16
CL2017000054A1 (es) 2017-06-23
CO2017000065A2 (es) 2017-05-19
IL250074A0 (en) 2017-03-30
AU2015227454A1 (en) 2016-02-04
SG11201610195UA (en) 2017-01-27
AU2017254894A1 (en) 2017-11-23
MX2017000613A (es) 2017-04-27
PH12016502607A1 (en) 2017-04-24
US20170152226A1 (en) 2017-06-01
CA2952557A1 (en) 2016-01-21
KR20170031097A (ko) 2017-03-20
WO2016008011A1 (en) 2016-01-21
EP3169683A1 (en) 2017-05-24
AU2016200541A1 (en) 2016-02-18
EP3169683A4 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
BR112017000714A2 (pt) indols funcionalizados e substituídos como agentes anti-câncer
IL272572B (en) Antibody preparations to treat cancer
PH12016501898B1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
BR112016011734A2 (pt) Indóis substituídos e funcionalizados como agentes anti-câncer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
BR112016022785A2 (pt) composto, composição farmacêutica, kit farmacêutico para tratar um câncer, e, métodos de tratamento de uma doença e/ou uma condição e/ou um distúrbio e de síntese de um composto
CL2015000926A1 (es) Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios.
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
BR112017003705A2 (pt) compostos contendo nitrogênio tricíclicos para o tratamento de infecção por neisseria gonorrhoea
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
PH12017500853A1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
BR112017014189A2 (pt) terapia de câncer com um parvovirus combinado com bevacizumabe
BR112017016333A2 (pt) compostos anticâncer
ITUB20155450A1 (it) Composizione per il trattamento delle dermatiti.
TR201401753A2 (tr) Nekroz tedavisine yönelik bir kompozisyon.
IL236381A0 (en) Pharmaceutical preparations for the treatment of cancer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]